Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx ...
Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - ...
Microsoft just fixed two critical Office vulnerabilities that can be triggered simply by previewing a file in Outlook. No double-clicking or macros required.
Physician adoption of ARCALYST as a second-line treatment was further supported by the 2025 ACC clinical guidance recommending IL-1 pathway inhibition after failure of NSAIDs and colchicine. Operator: ...
Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx The ...
The Trump administration explored giving the green light to a potential treatment for a broad swath of people on the autism spectrum — but a new drug approval scales back those ...
null ...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...
Apple Mail may label phishing emails as trusted senders. Learn why this happens and spot fake Apple alerts before scammers ...
The partnership sets a new standard for new age discovery, giving advisors powerful tools to uncover insights and accelerate transformation. The white label partnership with truCX allows us to extend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results